Syntara Limited · ASX:SNT
Syntara — NWR Virtual Healthcare Conference (March 2026)
29 slides from Syntara's conference presentation, Mar 25, 2026
Slide 1: NWR Virtual Healthcare Conference
For personal use only NWR Virtual Healthcare Conference Gary Phillips, CEO 25 March 2026
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT For personal use only This document contains These forward-looking forward-looking statements, statements are not guarantees including statements or predictions of future results, concerning Syntara’s future levels of performance, and financial position, plans, and the invo
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS For personal use only Australian-founded Backed by Multiple shots on Funded into 2027 with clinical stage specialist healthcare goal from additional near term data to drive drug developer. investors – Phase 2, Phase 1 and value over the next 43% institutional. preclinical asset
Slide 4: Syntara Board
SYNTARA BOARD Significant international pharmaceutical experience For personal use only Dr Kathleen Metters Dr Simon Green Gary Phillips Hashan De Silva Chair Non-Executive Director Chief Executive Officer Non-Executive Director • Former Senior Vice • Experienced senior global • 30+ years’ of operat
Slide 5: Shareholders & Cash
SHAREHOLDERS & CASH Financial Information (ASX: SNT) Share Price & Volume – YTD Share price – 10 March 2026 $0.030 For personal use only Close 0.1 Market cap A$49m 0.08 Cash balance – 31 December 2025 A$12.3m 0.06 Enterprise value A$36.7m 0.04 0.02 Institutional Ownership 31 Dec 25 0 Volume D&A Inco
Slide 6: The Year Ahead - Poised to Deliver Near Term Value
THE YEAR AHEAD - POISED TO DELIVER NEAR TERM VALUE TARGET DRUG INDICATION PARTNERS PHASE 1 PHASE 2 NEWS FLOW HEALTHY H1 2026 H2 2026 PATIENTS PARTICIPANTS For personal use only FDA approved development plan Myelofibrosis and partner engagement High Risk MDS Interim safety and Phase 2 initiation AZAL
Slide 7: Myelofibrosis
MYELOFIBROSIS A rare type of bone marrow cancer that disrupts the body’s normal production of blood cells KEY FACTS Myelofibrosis characterised by a build up of scar tissue • Orphan disease affects ~15 in 1m people (fibrosis) in bone marrow and abnormal proliferation of worldwide (USA ~ 20,000 patie
Slide 8: Myelofibrosis: Limited treatment options currently
MYELOFIBROSIS Limited treatment options currently Current standard of care (SoC): JAK inhibitors Amsulostat For personal use only In contrast to SoC, amsulostat intervenes at the Key• Class Factsof drugs used in the management of splenomegaly source, clearing fibrosis from the bone marrow and (enlar
Slide 9: Lysyl Oxidases in Myelofibrosis
LYSYL OXIDASES IN MYELOFIBROSIS Amsulostat designed to improve the bone marrow microenvironment Lysyl oxidase (LOX) gene family upregulated in the bone marrow (BM) of myelofibrosis patients For personal use only → Increased LOX activity adversely impacts BM health in several ways* Structural Effects
Slide 10: Lysyl Oxidases in Myelofibrosis: Amsulostat mode of action
LYSYL OXIDASES IN MYELOFIBROSIS Amsulostat designed to improve the bone marrow microenvironment Amsulostat inhibits lysyl oxidase (LOX) activity and has a multi-faceted mode of action For personal use only Amsulostat ✓Inhibits cross-link formation ✓Reduces mechanical stress ✓Inhibits signalling of a
Slide 11: MF-101 Add-on to JAK Inhibitor Ruxolitinib
MF-101 ADD-ON TO JAK INHIBITOR RUXOLITNIB Heterogenous population with a high disease burden STUDY DESIGN PATIENTS TREATED ENDPOINTS For personal use only Phase 2a open label study PRIMARY • Multi-national Phase 2a open 16 patients • evaluate to recruited safety, PK/PD, label study to evaluate safet
Slide 12: Total Symptom Score
TOTAL SYMPTOM SCORE Reduction at W24 Additional reduction past W24 73% (8/11) of patients achieved TSS50 at Week 24 or beyond * Pt continued past W38 # Pt completed W52 and study For personal use only Baseline TSS 37 10 52# 32 11* 18# 22# 45# 23# 10# 19# Symptom relief continues 0 for patients: TSS
Slide 13: Spleen Volume Reduction
SPLEEN VOLUME REDUCTION 44% (4/9) of patients achieved SVR25 at Week 24 or beyond For personal use only Improved spleen volume reduction: • At Week 24, 7/9 (78%) evaluable patients* experienced stable or reduced spleen volume with no increases in RUX dose. • 4/9 (44%) evaluable patients achieved SVR
Slide 14: Positive Top Line Phase 2a Data Highlights Amsulostat's Potential in Myelofibrosis
POSITIVE TOP LINE PHASE 2A DATA HIGHLIGHTS AMSULOSTAT’S POTENTIAL IN MYELOFIBROSIS For personal use only Improvements of 50% or Meaningful spleen Of the 7 patients Next stage of amsulostat more in total symptom volume reductions that completed 52 clinical and commercial score (TSS50) (SVR) were obse
Slide 15: Syntara Appoints Global Myelofibrosis Experts
SYNTARA APPOINTS GLOBAL MYELOFIBROSIS EXPERTS TO SUPPORT AMSULOSTAT DEVELOPMENT For personal use only Strategic Advisors to Myelofibrosis Clinical Advisory Board Syntara Board, Haematology • Professor Claire Harrison • Dr Adam Craig Professor of Myeloproliferative Neoplasms and Former CEO of CTI Bio
Slide 16: Strong Interest in MF Assets from Strategics
STRONG INTEREST IN MF ASSETS FROM STRATEGICS Target / Acquiror / / / / For personal use only DATE OF ANNOUNCEMENT DEC-2024 FEB-2024 JUNE-2023 JULY-2022 Drug Name Elritercept Pelabresib Pacritinib Momelotinib Lead Indication / MDS and MF Myelofibrosis Myelofibrosis Myelofibrosis Phase (at transaction
Slide 17: MDS Is a Blood Cancer
MDS IS A BLOOD CANCER Diverse bone marrow disorders characterized by inadequate production of healthy blood cells High unmet need with current standard of care For personal use only Key Facts • Therapy for low-risk MDS patients is aimed at improving cytopenia(s) to prevent complications • In interme
Slide 18: Lysyl Oxidases and MDS
LYSYL OXIDASES AND MDS HYPOTHESIS: Lysyl oxidase activity is increased Correction of elevated lysyl oxidase Impressive preclinical results in bone marrow aspirates from activity in bone marrow published in Nature For personal use only MDS patients. microenvironment could be of • Amsulostat on top of
Slide 19: Recruitment Ongoing for Two Studies in MDS
RECRUITMENT ONGOING FOR TWO STUDIES IN MDS AZALOX: Phase 1b/2a open label study MESSAGE: Phase 1b/2a open label study to to evaluate safety, PK/PD and efficacy evaluate safety, PK/PD and efficacy For personal use only • High risk MDS or intermediate-2 to high • Transfusion-dependent low/intermediate
Slide 20: Skin Scarring
SKIN SCARRING Skin Scarring as a Global Disease • 100 million new scars annually post The global scar treatment market projected For personal use only surgery in the developed world to reach $50–55 billion by 2030 alone • Surgical, traumatic, burn, acne, cosmetic, obstetric etc • A lifelong conditio
Slide 21: Standard of Care
STANDARD OF CARE Fragmented, Ineffective and Outdated • Silicone sheeting (none to v limited effect) • Steroid injections (temporary; high relapse) For personal use only • Laser therapy (expensive; operator dependent) • Surgery (expensive, recurrence common, especially in keloids) THE WHITESPACE OPP
Slide 22: Syntara, UWA and Fiona Wood Foundation
SYNTARA, UWA AND FIONA WOOD FOUNDATION Long-term collaboration driving translation of basic science into the clinic and patient benefit SOLARIA2 Findings Multi-year pre-clinical program For personal use only Completed clinical studies • Solaria 1; SNT-6302 healthy volunteers Images at day one (L) an
Slide 23: Phase 1 First in Human Integrated Patient Study
PHASE 1 FIRST IN HUMAN INTEGRATED PATIENT STUDY For personal use only Healthy Volunteer Phase 1a Single Ascending Dose ✓ Dose-dependent target engagement confirmed “We now understand the biology well enough to target stiffness directly rather than just calming inflammation around it. LOXL activity s
Slide 24: Phase 1 First in Human Integrated Patient Study: Trial Design
PHASE 1 FIRST IN HUMAN INTEGRATED PATIENT STUDY Trial design optimised for inclusion criteria and endpoints For personal use only PRIMARY ENDPOINT ▪ Safety TEAEs Images at day one (L) and day 90 (R) show a significant increase in blood vessel density SECONDARY ENDPOINTS OCT imaging technology (as fo
Slide 25: Neuroinflammation
NEUROINFLAMMATION SNT-4728 is a dual SSAO & MAO-B Parkinson’s Disease and IRBD inhibitor, representing a novel anti-inflammatory and • Prodromal symptoms, such as isolating REM sleep behavior For personal use only neuroprotective approach disorder (iRBD), proceed the onset of motor cognitive dysfunc
Slide 26: Using a Sleep Disorder to Target Parkinson's Disease
USING A SLEEP DISORDER TO TARGET PARKINSON’S DISEASE Patients with iRBD represent a For personal use only prodromal stage of PD, where disease modifying (slowing) therapies might have their greatest impact. • Unmet medical need as there is currently no approved treatment; current standard of care is
Slide 27: Parkinson's UK Funded Trial
PARKINSON’S UK FUNDED TRIAL Phase 2 multi-centre, placebo- For personal use only Study funded by Parkinson’s UK controlled study assessing effect of and is being run at sites in SNT-4728 on microglia activation in Sydney, Australia and Oxford, UK patients with iRBD 40 patients (3:1 randomization), d
Slide 28: The Year Ahead - Poised to Deliver Near Term Value
THE YEAR AHEAD - POISED TO DELIVER NEAR TERM VALUE TARGET DRUG INDICATION PARTNERS PHASE 1 PHASE 2 NEWS FLOW HEALTHY H1 2026 H2 2026 PATIENTS PARTICIPANTS For personal use only FDA approved development plan Myelofibrosis and partner engagement High Risk MDS Interim safety and Phase 2 initiation AZAL
Slide 29: Syntara Limited
For personal use only Syntara Limited ABN 75 082 811 630 Gary Phillips Chief Executive Officer www.syntaraTX.com.au gary.phillips@syntaraTX.com.au
Syntara — NWR Virtual Healthcare Conference (March 2026) on 6ix